Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe

NCT01890993 · Completed

Last updated 2026-05-28

This study looked back at medical records to compare the effects and safety of two diabetes medications, liraglutide and DPP-4 inhibitors, in adults with type 2 diabetes treated in European primary care settings.

Status Completed The study has finished.

Type Observational

Participants 952 people

Who can join all sexes

Timeline Started 2013-08 · est. completion 2014-06

Where 4 sites · France, Germany, Spain, United Kingdom

What this study is testing ClinicalTrials.gov NCT01890993 ↗

Description as written by the study sponsor.

This study is conducted in Europe. The aim of this study is to demonstrate the clinical effectiveness and safety of liraglutide and dipeptidyl peptidase-4 (DPP-4) inhibitor therapy in routine primary care in Europe.

Treatments tested

liraglutide Drug

Anonymised patient level data will be collected by the patients' own general practitioner and electronic case report form (eCRF) will be used to capture the data.

Main thing measured	Change in HbA1c (glycosylated haemoglobin)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01890993 ↗